Clinical data | |
---|---|
Pronunciation | /ˌflʊərəˈlænər/ FLOOR-ə-LAN-ər |
Trade names | Bravecto, Exzolt |
Other names |
|
License data |
|
Routes of administration | By mouth |
ATCvet code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 20–27%;[1] reduced in the fasted state[2] |
Elimination half-life | 9.3–16.2 days[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.215.812 |
Chemical and physical data | |
Formula | C22H17Cl2F6N3O3 |
Molar mass | 556.29 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
|
Fluralaner (INN)[4] is a systemic insecticide and acaricide that is administered orally[5] or topically.[6] The U.S. Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014[7] and Bravecto Plus as a topical treatment for cats in November 2019,[8] with warnings about possible side effects in both species.[9] The EU approved the drug in February 2014.[10] Australia approved it for the treatment and prevention of ticks and fleas on dogs in January 2015.[11] For treating mites in chickens, a solution for use in drinking water is available under the name Exzolt;[12] it was introduced by the EU in 2017.[13]